Transmitted/Founder Viruses Rapidly Escape from CD8+ T Cell Responses in Acute Hepatitis C Virus Infection.
The interaction between hepatitis C virus (HCV) and cellular immune responses during very early infection is critical for disease outcome. To date, the impact of antigen-specific cellular immune responses on the evolution of the viral population establishing infection and on potential escape has not been studied. Understanding these early host-virus dynamics is important for the development of a preventative vaccine. Three subjects who were followed longitudinally from the detection of viremia preseroconversion until disease outcome were analyzed. The evolution of transmitted/founder (T/F) viruses was undertaken using deep sequencing. CD8(+) T cell responses were measured via enzyme-linked immunosorbent spot (ELISpot) assay using HLA class I-restricted T/F epitopes. T/F viruses were rapidly extinguished in all subjects associated with either viral clearance (n = 1) or replacement with viral variants leading to establishment of chronic infection (n = 2). CD8(+) T cell responses against 11 T/F epitopes were detectable by 33 to 44 days postinfection, and 5 of these epitopes had not previously been reported. These responses declined rapidly in those who became chronically infected and were maintained in the subject who cleared infection. Higher-magnitude CD8(+) T cell responses were associated with rapid development of immune escape variants at a rate of up to 0.1 per day. Rapid escape from CD8(+) T cell responses has been quantified for the first time in the early phase of primary HCV infection. These rapid escape dynamics were associated with higher-magnitude CD8(+) T cell responses. These findings raise questions regarding optimal selection of immunogens for HCV vaccine development and suggest that detailed analysis of individual epitopes may be required.


OBJECTIVE
A major limitation in our detailed understanding of the role of immune response in HCV clearance has been the lack of data on very early primary infection when the transmitted viral variants successfully establish the acute infection. This study was made possible through the availability of specimens from a unique cohort of asymptomatic primary infection cases in whom the first available viremic samples were collected approximately 3 weeks postinfection and at regular intervals thereafter. The study included detailed examination of both the evolution of the viral population and the host cellular immune responses against the T/F viruses. The findings here provide the first evidence of host cellular responses targeting T/F variants and imposing a strong selective force toward viral escape. The results of this study provide useful insight on how virus escapes the host response and consequently on future analysis of vaccine-induced immunity.
Systems Medicine, Inflammation and Infection Research Centre, School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, New South Wales, Australia.
Rowena A
RA
Bull
Systems Medicine, Inflammation and Infection Research Centre, School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, New South Wales, Australia.
Preston
P
Leung
School of Anatomy, Physiology and Human Biology, University of Western Australia, Nedlands, Western Australia, Australia Institute for Immunology and Infectious Disease, Murdoch University, Perth, Western Australia, Australia.
Silvana
S
Gaudieri
School of Anatomy, Physiology and Human Biology, University of Western Australia, Nedlands, Western Australia, Australia.
Pooja
P
Deshpande
Systems Medicine, Inflammation and Infection Research Centre, School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, New South Wales, Australia.
Barbara
B
Cameron
Systems Medicine, Inflammation and Infection Research Centre, School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, New South Wales, Australia.
Melanie
M
Walker
Institute for Immunology and Infectious Disease, Murdoch University, Perth, Western Australia, Australia.
Abha
A
Chopra
Systems Medicine, Inflammation and Infection Research Centre, School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, New South Wales, Australia.
Andrew R
AR
Lloyd
Systems Medicine, Inflammation and Infection Research Centre, School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, New South Wales, Australia luciani@unsw.edu.au.
Fabio
F
Luciani
D000208:Acute Disease; D000328:Adult; D000595:Amino Acid Sequence; D000914:Antibodies, Viral / Q000097:blood; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D018450:Disease Progression; D018984:Epitopes, T-Lymphocyte / Q000235:genetics / Q000276:immunology; D019143:Evolution, Molecular; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity*; D018963:Hepatitis Antigens / Q000235:genetics / Q000276:immunology; D006526:Hepatitis C / Q000276:immunology* / Q000821:virology*; D019698:Hepatitis C, Chronic / Q000276:immunology / Q000821:virology; D054884:Host-Pathogen Interactions; D006801:Humans; D007111:Immunity, Cellular; D008297:Male; D009154:Mutation; D020641:Polymorphism, Single Nucleotide; D012641:Selection, Genetic; D013997:Time Factors; D014761:Viral Hepatitis Vaccines / Q000276:immunology; D019562:Viral Load; D055815:Young Adult
D000914:Antibodies, Viral; D018984:Epitopes, T-Lymphocyte; D018963:Hepatitis Antigens; D014761:Viral Hepatitis Vaccines